DMD: Prosensa to Present Webcasts on Drug Development

Drisapersen developer Prosensa will update the investor community via Jan. 16 webcast and the DMD patient community via Jan. 21 webcast

by Quest Staff on January 16, 2014 - 11:58am

Dutch biopharmaceutical company Prosensa, developer of the experimental drug drisapersen and other experimental compounds for Duchenne muscular dystrophy (DMD), will update the investor community via a Thursday, Jan. 16, 2014, presentation at the J.P. Morgan Healthcare Conference in San Francisco. The presentation will be webcast at 10 a.m. Pacific time/1 p.m. Eastern time.

On Tuesday, Jan. 21, at 8 a.m. Eastern time, Prosensa will conduct a separate webinar for DMD patients and families.

See Prosensa Events & Presentations for links to both webcasts. See also Prosensa’s Jan. 13 press release for more information.

Be sure to stay with Quest for the latest updates. Check back in the coming days for recaps on the Prosensa/drisapersen webcasts.

No votes yet
MDA cannot respond to questions asked in the comments field. For help with questions, contact your local MDA office or clinic or email publications@mdausa.org. See comment policy